This dose selection question is a concern, and I do remember Chel raising this recently. Obviously, we have lots of evidence for 2mg/kg twice weekly / 6 weeks going back through hundreds of 2b, SAS, and EAP patients. Is there a chance this was left out because we have enough data on it? And it might ultimately still be the selected dose for trial if the others fail to show similar efficacy? This is a blind spot for me - but i'd really love some clarity on it, especially now. Will email Simon White with this too.
Ann: PAR Reports Successful Primary Endpoint in Phase 2 Trial, page-40
-
- There are more pages in this discussion • 76 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
-0.005(2.38%) |
Mkt cap ! $71.73M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 21.0¢ | 20.0¢ | $152.8K | 744.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 78174 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 84426 | 5 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |